Cancer vaccine market to hit $7B by 2015

Spurred by the recent approval of Dendreon's prostate cancer vaccine Provenge, a new report predicts that the cancer vaccine market will swell to a $7 billion industry by 2015. There are six types of vaccines in development, according to the report: antigen/adjuvant vaccines, DNA vaccines, vector-based vaccines, tumor cell vaccines, dendritic cell vaccines and anti-idiotype vaccines. Release

Suggested Articles

The scientific community has again been caught off guard and industry officials are talking about implementing better preventive measures.

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…

NIH and Moderna will need a coronavirus vaccine manufacturer, and and no major pharmaceutical company has stepped up.